159 related articles for article (PubMed ID: 11292186)
1. Acquired von Willebrand syndrome in systemic lupus erythematodes.
Michiels JJ; Schroyens W; van der Planken M; Berneman Z
Clin Appl Thromb Hemost; 2001 Apr; 7(2):106-12. PubMed ID: 11292186
[TBL] [Abstract][Full Text] [Related]
2. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
[TBL] [Abstract][Full Text] [Related]
3. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
4. Acquired type 3-like von Willebrand syndrome preceded full-blown systemic lupus erythematosus.
Niiya M; Niiya K; Takazawa Y; Hayashi Y; Tanio Y; Kushiro M; Tanimizu M; Hasegawa H; Tanimoto M
Blood Coagul Fibrinolysis; 2002 Jun; 13(4):361-5. PubMed ID: 12032403
[TBL] [Abstract][Full Text] [Related]
5. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of inhibitors in acquired von Willebrand syndrome.
Mohri H; Motomura S; Kanamori H; Matsuzaki M; Watanabe S; Maruta A; Kodama F; Okubo T
Blood; 1998 May; 91(10):3623-9. PubMed ID: 9572997
[TBL] [Abstract][Full Text] [Related]
7. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):577-88. PubMed ID: 16977568
[TBL] [Abstract][Full Text] [Related]
8. Atypical variant of acquired von Willebrand syndrome in Wilms tumor: is hyaluronic acid secreted by nephroblastoma cells the cause?
Michiels J; Schroyens W; Berneman Z; van der Planken M
Clin Appl Thromb Hemost; 2001 Apr; 7(2):102-5. PubMed ID: 11292185
[TBL] [Abstract][Full Text] [Related]
9. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
10. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine.
Michiels JJ; Schroyens W; Berneman Z; van der Planken M
Clin Appl Thromb Hemost; 2001 Apr; 7(2):113-5. PubMed ID: 11292187
[TBL] [Abstract][Full Text] [Related]
11. Von Willebrand's disease: case report and review of literature.
Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M
Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675
[TBL] [Abstract][Full Text] [Related]
12. Systemic lupus erythematosus complicated by acquired von Willebrand's syndrome.
Hong S; Lee J; Chi H; Lee C; Nah S; Kim Y; Oh J; Moon H; Yoo B
Lupus; 2008 Sep; 17(9):846-8. PubMed ID: 18755868
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches.
Federici AB; Stabile F; Castaman G; Canciani MT; Mannucci PM
Blood; 1998 Oct; 92(8):2707-11. PubMed ID: 9763553
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
[TBL] [Abstract][Full Text] [Related]
15. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
[TBL] [Abstract][Full Text] [Related]
17. Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome.
Casonato A; Pontara E; Doria A; Bertomoro A; Cattini MG; Gambari PF; Girolami A
Br J Haematol; 2002 Mar; 116(4):899-904. PubMed ID: 11886398
[TBL] [Abstract][Full Text] [Related]
18. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies.
Favaloro EJ; Kershaw G; Bukuya M; Hertzberg M; Koutts J
Haemophilia; 2001 Mar; 7(2):180-9. PubMed ID: 11260278
[TBL] [Abstract][Full Text] [Related]
19. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
20. An atypical manifestation of acquired von Willebrand syndrome (AVWS) associated with systemic lupus erythematosus (SLE).
Kasatkar P; Ghosh K; Shetty S
Ann Hematol; 2014 Jan; 93(1):173-5. PubMed ID: 23625134
[No Abstract] [Full Text] [Related]
[Next] [New Search]
